Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis

The Lancet Neurology

Volumn 16, Issue 1, 2017, Pages 55-

  Irwin, David J ^a   Grossman, Murray ^a   Weintraub, Daniel ^a,b   Hurtig, Howard I ^a   Duda, John E ^a,b   Xie, Sharon X ^a   Lee, Edward B ^a   Van Deerlin, Vivianna M ^a   Lopez, Oscar L ^c   Kofler, Julia K ^c   Nelson, Peter T ^d,e   Jicha, Gregory A ^d   Woltjer, Randy ^f   Quinn, Joseph F ^f,i   Kaye, Jeffery ^f   Leverenz, James B ^g,i   Tsuang, Debby ^i,j   Longfellow, Katelan ^i,j   Yearout, Dora ^i,j   Kukull, Walter ⁱ   Keene, C Dirk ⁱ   Montine, Thomas J ^h,i   Zabetian, Cyrus P ^i,j   Trojanowski, John Q ^a   more..

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

^e UNIVERSITY OF KENTUCKY   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

^h STANFORD UNIVERSITY   (United States)

ⁱ UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^j VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DEMENTIA; DISEASE DURATION; FEMALE; HISTOPATHOLOGY; HUMAN; LEWY BODY; MAJOR CLINICAL STUDY; MALE; NEUROFIBRILLARY TANGLE; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENILE PLAQUE; SURVIVAL RATE; SURVIVAL TIME; SYNUCLEINOPATHY; AUTOPSY; COHORT ANALYSIS; DIFFUSE LEWY BODY DISEASE; GENETICS; MEDLINE; METABOLISM; MUTATION; PARKINSON DISEASE; PATHOLOGY; RECEIVER OPERATING CHARACTERISTIC; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; AUTOPSY; COHORT STUDIES; DEMENTIA; FEMALE; HUMANS; LEWY BODIES; LEWY BODY DISEASE; LINEAR MODELS; MALE; MUTATION; PARKINSON DISEASE; PUBMED; ROC CURVE;

EID: 85004140744     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(16)30291-5     Document Type: Article

References (30)

1. 1 Emre, M, Aarsland, D, Brown, R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 22 (2007), 1689–1707.
2. 2 McKeith, IG, Dickson, DW, Lowe, J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65 (2005), 1863–1872.
3. 3 Lippa, CF, Duda, JE, Grossman, M, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 68 (2007), 812–819.
4. 4 Montine, TJ, Phelps, CH, Beach, TG, et al. National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol 123 (2012), 1–11.
5. 5 Aarsland, D, Andersen, K, Larsen, JP, Lolk, A, Kragh-Sorensen, P, Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 60 (2003), 387–392.
6. 6 Irwin, DJ, White, MT, Toledo, JB, et al. Neuropathologic substrates of Parkinson disease dementia. Ann Neurol 72 (2012), 587–598.
7. 7 Ballard, C, Ziabreva, I, Perry, R, et al. Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology 67 (2006), 1931–1934.
8. 8 Compta, Y, Parkkinen, L, O'Sullivan, SS, et al. Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?. Brain 134 (2011), 1493–1505.
9. 9 Irwin, DJ, Lee, VM, Trojanowski, JQ, Parkinson's disease dementia: convergence of alpha-synuclein, tau and amyloid-beta pathologies. Nature Rev Neurosci 14 (2013), 626–636.
10. 10 Gibb, WR, Lees, AJ, The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 51 (1988), 745–752.
11. 11 Tsuang, D, Leverenz, JB, Lopez, OL, et al. APOE epsilon4 increases risk for dementia in pure synucleinopathies. JAMA Neurol 70 (2013), 223–228.
12. 12 Tsuang, D, Leverenz, JB, Lopez, OL, et al. GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology 79 (2012), 1944–1950.
13. 13 Hyman, BT, Phelps, CH, Beach, TG, et al. National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 8 (2012), 1–13.
14. 14 Nalls, MA, Pankratz, N, Lill, CM, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet 46 (2014), 989–993.
15. 15 Mata, IF, Leverenz, JB, Weintraub, D, et al. GBA variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease. Mov Disord 31 (2016), 95–102.
16. 16 Raftery, AE, Bayesian model selection in social research. Sociol Methodol 25 (1995), 111–163.
17. 17 Steyerberg, EW, Harrell, FE Jr, Borsboom, GJ, Eijkemans, MJ, Vergouwe, Y, Habbema, JD, Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 54 (2001), 774–781.
18. 18 Jellinger, KA, Seppi, K, Wenning, GK, Poewe, W, Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. J Neural Transm 109 (2002), 329–339.
19. 19 Sabbagh, MN, Adler, CH, Lahti, TJ, et al. Parkinson disease with dementia: comparing patients with and without Alzheimer pathology. Alzheimer Dis Assoc Disord 23 (2009), 295–297.
20. 20 Ruffmann, C, Calboli, FC, Bravi, I, et al. Cortical Lewy bodies and Abeta burden are associated with prevalence and timing of dementia in Lewy body diseases. Neuropathol Appl Neurobiol 42 (2016), 436–450.
21. 21 Howlett, DR, Whitfield, D, Johnson, M, et al. Regional multiple pathology scores are associated with cognitive decline in Lewy body dementias. Brain Pathol 25 (2015), 401–408.
22. 22 Halliday, G, Hely, M, Reid, W, Morris, J, The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol 115 (2008), 409–415.
23. 23 Kang, JH, Irwin, DJ, Chen-Plotkin, A, et al. Association of cerebrospinal fluid Aβ1-42, t-tau, p-tau181 and α-synuclein levels with clinical features of early drug naïve Parkinson's disease patients. JAMA Neurol 70 (2013), 1277–1287.
24. 24 Lee, VM, Giasson, BI, Trojanowski, JQ, More than just two peas in a pod: common amyloidogenic properties of tau and alpha-synuclein in neurodegenerative diseases. Trends Neurosci 27 (2004), 129–134.
25. 25 Guo, JL, Covell, DJ, Daniels, JP, et al. Distinct alpha-synuclein strains differentially promote tau inclusions in neurons. Cell 154 (2013), 103–117.
26. 26 Pankratz, N, Beecham, GW, DeStefano, AL, et al. Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. Ann Neurol 71 (2012), 370–384.
27. 27 Litvan, I, Goldman, JG, Troster, AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord 27 (2012), 349–356.
28. 28 Pigott, K, Rick, J, Xie, SX, et al. Longitudinal study of normal cognition in Parkinson disease. Neurology 85 (2015), 1276–1282.
29. 29 Selikhova, M, Williams, DR, Kempster, PA, Holton, JL, Revesz, T, Lees, AJ, A clinico-pathological study of subtypes in Parkinson's disease. Brain 132 (2009), 2947–2957.
30. 30 Montine, TJ, Monsell, SE, Beach, TG, et al. Multisite assessment of NIA–AA guidelines for the neuropathologic evaluation of Alzheimer's disease. Alzheimers Dement 12 (2016), 164–169.